U.S. Food and Drug Administration and European Medicines Agency Reach Landmark Decisions on Critical Path Institute’s Clinical Trial Simulation Tool for Alzheimer’s Disease
CFAST Announces Parkinson’s Disease Drug Development Milestone: Release and Availability of a PD Therapeutic Area Data Standard
The National Multiple Sclerosis Society and Critical Path Institute Create the Multiple Sclerosis Outcome Assessments Consortium
CDISC, C-Path and FDA Collaborate to Develop Data Standards to Streamline Path to New Therapies The Clinical Data Interchange Standards Consortium (CDISC) and the Critical Path Institute (C-Path) announce the signing of a part
European Medicines Agency Deems Imaging Biomarker a Qualified Measure to Select Patients with Early Stages of Cognitive Impairment for Alzheimer’s Disease Clinical Trials Based on a request for regulatory review by Critical Path Institute’s (C-Path) Coalition Against Major Diseases (CAMD), the
